Dechra Pharmaceuticals PLC is engaged in veterinary pharmaceuticals and related products business. The Company is engaged in development, manufacture and marketing of products for veterinarians. Its segments include European Pharmaceuticals, North American (NA) Pharmaceuticals and Pharmaceuticals Research and Development. The European Pharmaceuticals Segment includes Dechra Veterinary Products Europe, Genera and Dechra Pharmaceuticals Manufacturing. It manufactures and markets Companion Animal, Equine and Food producing Animal Products. It includes third party manufacturing and other non-core activities sales. The NA Pharmaceuticals Segment consists of Dechra Veterinary Products US, Putney, Dechra Veterinary Products Canada, and Dechra-Brovel that sell Companion Animal and Equine Products into those territories. The Pharmaceuticals Research and Development Segment includes its pharmaceutical research and development activities. Its offerings include Osphos and Vetoryl.
Industry, Sector and Symbol:
- Sector: Healthcare
- Industry: Veterinary Drugs
- Sub-Industry: N/A
- Symbol: LON:DPH
- CUSIP: N/A
- Web: www.dechra.com/
Capitalization:- Market Cap: £1.87 billion
- Outstanding Shares: 92,818,000
Average Prices:- 50 Day Moving Avg: GBX 1,904.89
- 200 Day Moving Avg: GBX 1,783.03
- 52 Week Range: GBX 1,225 - GBX 2,149
P/E:- Trailing P/E Ratio: 71.86
- P/E Growth: 0.00
Sales & Book Value:- Annual Revenue: £359.28 million
- Price / Sales: 5.18
- Book Value: GBX 3.23 per share
- Price / Book: 6.21
Profitability:- EBIDTA: £77.7 million
- Net Margins: 7.39%
- Return on Equity: 9.06%
- Return on Assets: 4.33%
Misc:- Average Volume: 155,293 shs.
Frequently Asked Questions for Dechra Pharmaceuticals plc (LON:DPH)
What is Dechra Pharmaceuticals plc's stock symbol?
Dechra Pharmaceuticals plc trades on the London Stock Exchange (LON) under the ticker symbol "DPH."
How often does Dechra Pharmaceuticals plc pay dividends? What is the dividend yield for Dechra Pharmaceuticals plc?
Dechra Pharmaceuticals plc declared a dividend on Monday, September 4th. Investors of record on Thursday, October 26th will be given a dividend of GBX 15.33 per share on Friday, November 17th. This represents a dividend yield of 0.74%. The ex-dividend date is Thursday, October 26th. This is a positive change from Dechra Pharmaceuticals plc's previous dividend of $6.11. The official announcement can be accessed at this link. View Dechra Pharmaceuticals plc's Dividend History.
Where is Dechra Pharmaceuticals plc's stock going? Where will Dechra Pharmaceuticals plc's stock price be in 2017?
6 equities research analysts have issued twelve-month price targets for Dechra Pharmaceuticals plc's stock. Their forecasts range from GBX 1,550 to GBX 1,890. On average, they anticipate Dechra Pharmaceuticals plc's stock price to reach GBX 1,784 in the next twelve months. View Analyst Ratings for Dechra Pharmaceuticals plc.
Who are some of Dechra Pharmaceuticals plc's key competitors?
Some companies that are related to Dechra Pharmaceuticals plc include WuXi PharmaTech (Cayman) (WX), Cotiviti Holdings (COTV), Enerplus Corp (ERF), Axovant Sciences Ltd (AXON), Hikma Pharmaceuticals Plc (HIK), BTG plc (BTG), Indivior PLC (INDV), Hutchison China MediTech Limited (HCM), Abcam Plc (ABC), Udg Healthcare PLC (UDG), Biohaven Pharmaceutical Holding Co Ltd (BHVN), TherapeuticsMD (TXMD), TherapeuticsMD (TXMD), Genus plc (GNS), Knight Therapeutics (GUD), Knight Therapeutics (GUD), Clinigen Group PLC (CLIN) and Asante Solutions (PUMP).
Who are Dechra Pharmaceuticals plc's key executives?
Dechra Pharmaceuticals plc's management team includes the folowing people:
- Ian David Page, Chief Executive Officer, Executive Director
- Richard Cotton, Chief Financial Officer
- Mike Eldred, President, North America
- Suzana Cross, General Counsel, Company Secretary
- Anthony Gerard Griffin, Managing Director - Dechra Veterinary Products Europe, Executive Director
- Katy Clough, Group HR Director
- Susan Longhofer, Regulatory Affairs and Business Development Group Director
- Allen Mellor, Group IT Director
- Tony Rice, Non-Executive Chairman of the Board
- Lawson Macartney Ph.D., Non-Executive Director
How do I buy Dechra Pharmaceuticals plc stock?
Shares of Dechra Pharmaceuticals plc and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
What is Dechra Pharmaceuticals plc's stock price today?
One share of Dechra Pharmaceuticals plc stock can currently be purchased for approximately GBX 2,005.
MarketBeat Community Rating for Dechra Pharmaceuticals plc (LON DPH)MarketBeat's community ratings are surveys of what our community members think about Dechra Pharmaceuticals plc and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for Dechra Pharmaceuticals plc (LON:DPH) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | 3 Hold Ratings, 3 Buy Ratings |
| Consensus Rating: | Buy (Score: 2.50) |
| Consensus Price Target: | GBX 1,784 |
Analysts' Ratings History for Dechra Pharmaceuticals plc (LON:DPH)
Show:
| Date | Firm | Action | Rating | Price Target | Details |
|---|
| 9/5/2017 | Jefferies Group LLC | Boost Price Target | Hold | GBX 1,565 -> GBX 1,868 |  |
| 7/11/2017 | Stifel Nicolaus | Reiterated Rating | Hold | GBX 1,550 | |
| 7/6/2017 | Investec | Reiterated Rating | Buy | GBX 1,840 | |
| 7/6/2017 | N+1 Singer | Reiterated Rating | Buy | GBX 1,666 | |
| 7/6/2017 | Numis Securities Ltd | Reiterated Rating | Add | GBX 1,890 | |
| 4/20/2017 | Panmure Gordon | Reiterated Rating | Under Review | | |
| 3/14/2017 | Royal Bank Of Canada | Boost Price Target | Outperform | GBX 1,630 -> GBX 1,890 | |
| 2/24/2017 | FinnCap | Reiterated Rating | Under Review | | |
(Data available from 9/20/2015 forward)
Earnings History for Dechra Pharmaceuticals plc (LON:DPH)
No earnings announcements for this company have been tracked by MarketBeat.com
Earnings Estimates for Dechra Pharmaceuticals plc (LON:DPH)Current Year EPS Consensus Estimate: $63.11 EPS
Dividend History by Quarter for Dechra Pharmaceuticals plc (LON DPH)| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
| 9/4/2017 | | GBX 15.33 | 0.74% | 10/26/2017 | 10/26/2017 | 11/17/2017 |
| 2/27/2017 | | GBX 6.11 | 0.38% | 3/9/2017 | 3/9/2017 | 4/7/2017 |
| 9/5/2016 | | GBX 12.91 | 0.92% | 10/27/2016 | 10/27/2016 | 11/18/2016 |
| 2/22/2016 | | GBX 5.55 | 0.47% | 3/10/2016 | 3/10/2016 | 4/6/2016 |
| 9/7/2015 | | GBX 11.82 | 1.26% | 10/29/2015 | 10/29/2015 | 11/20/2015 |
| 9/8/2014 | | GBX 10.65 | 1.4% | 11/6/2014 | 11/6/2014 | 11/21/2014 |
| 2/25/2014 | | GBX 4.75 | 0.68% | 3/12/2014 | 3/12/2014 | 4/8/2014 |
(Data available from 1/1/2013 forward)
Insider Trading and Institutional Ownership History for Dechra Pharmaceuticals plc (LON:DPH)Insider Trades by Quarter for Dechra Pharmaceuticals plc (LON:DPH)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 9/19/2017 | Ian Page | Insider | Sell | 54,910 | GBX 2,024 | £1,111,378.40 | |
| 6/21/2017 | Ian Page | Insider | Sell | 134,500 | GBX 1,927 | £2,591,815 | |
| 5/2/2017 | Ian Page | Insider | Sell | 1,630 | GBX 1,715 | £27,954.50 | |
| 3/21/2017 | Tony Griffin | Insider | Sell | 3,500 | GBX 1,676 | £58,660 | |
| 11/30/2016 | Tony Griffin | Insider | Sell | 17,133 | GBX 1,292 | £221,358.36 | |
| 6/3/2016 | Rice,Tony | Insider | Buy | 20,000 | GBX 1,141 | £228,200 | |
| 3/21/2016 | Nesmes,Anne-Francoise | Insider | Sell | 3,100 | GBX 1,208 | £37,448 | |
| 9/9/2015 | Nesmes,Anne-Francoise | Insider | Sell | 18,319 | GBX 940 | £172,198.60 | |
(Data available from 1/1/2013 forward)
Headline Trends for Dechra Pharmaceuticals plc (LON:DPH)
Latest Headlines for Dechra Pharmaceuticals plc (LON:DPH)
| Source: |
|
| Date | Headline |
|---|
 | Dechra Pharmaceuticals plc (DPH) Insider Ian Page Sells 54,910 Shares
www.americanbankingnews.com - September 20 at 1:16 PM |
 | ETFs with exposure to Dechra Pharmaceuticals PLC : September 15, 2017
finance.yahoo.com - September 15 at 6:26 PM |
| Dechra Pharmaceuticals PLC :DPH-GB: Earnings Analysis: 2017 By the Numbers : September 14, 2017
finance.yahoo.com - September 14 at 12:19 AM |
| What Is Dechra Pharmaceuticals plc’s (LSE:DPH) Share Price Doing?
finance.yahoo.com - September 11 at 3:43 PM |
| [$$] Dechra sales boosted by acquisitions and new drugs
finance.yahoo.com - September 4 at 10:43 PM |
| Dechra Pharmaceuticals PLC - 20 Years of Strategic Growth
finance.yahoo.com - September 4 at 5:40 PM |
| Edited Transcript of DPH.L earnings conference call or presentation 4-Sep-17 9:30am GMT
finance.yahoo.com - September 4 at 5:40 PM |
 | Dechra FY Pre-tax Profit Rises; Says Current Trading In Line With Board View
www.rttnews.com - September 4 at 3:30 AM |
| Dechra Pharmaceuticals plc (DPH) Receives Average Recommendation of "Buy" from Analysts
www.americanbankingnews.com - August 29 at 12:36 PM |
| Dechra Pharmaceuticals plc (DPH) Scheduled to Post Quarterly Earnings on Monday
www.americanbankingnews.com - August 28 at 1:46 AM |
| Dechra Pharmaceuticals plc (DPH) Given Average Rating of "Buy" by Analysts
www.americanbankingnews.com - August 4 at 12:44 PM |
| Dechra Pharmaceuticals plc (DPH) Receives Average Rating of "Buy" from Brokerages
www.americanbankingnews.com - July 10 at 12:49 PM |
| Dechra Pharmaceuticals plc's (LON:DPH) Add Rating Reaffirmed at Numis Securities Ltd
www.americanbankingnews.com - July 9 at 9:25 AM |
| Dechra Pharmaceuticals plc (LON:DPH) Receives Buy Rating from N+1 Singer
www.americanbankingnews.com - July 9 at 7:30 AM |
| Dechra Pharmaceuticals plc (LON:DPH) Earns Buy Rating from Investec
www.americanbankingnews.com - July 6 at 9:02 AM |
| Dechra Pharma Says FY Trading In Line With Its View
www.rttnews.com - July 6 at 4:47 AM |
| Dechra Pharmaceuticals plc (DPH) Insider Sells £2,591,815 in Stock
www.americanbankingnews.com - June 22 at 1:32 PM |
| Dechra Pharmaceuticals plc (DPH) Given Average Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - June 13 at 12:50 PM |
| Dechra Pharmaceuticals plc (DPH) Given Consensus Recommendation of "Buy" by Analysts
www.americanbankingnews.com - May 19 at 12:54 PM |
| Dechra Pharmaceuticals plc (DPH) Insider Ian Page Sells 1,630 Shares
www.americanbankingnews.com - May 6 at 12:20 AM |
| Dechra Pharmaceuticals plc (DPH) Insider Sells £27,954.50 in Stock
www.americanbankingnews.com - May 4 at 7:06 AM |
| Dechra Pharmaceuticals plc (DPH) Given Average Rating of "Buy" by Brokerages
www.americanbankingnews.com - April 24 at 2:56 PM |
| Dechra Pharmaceuticals plc (DPH) Receives "Under Review" Rating from Panmure Gordon
www.americanbankingnews.com - April 20 at 7:37 PM |
| Dechra Pharmaceuticals Plc – Value Analysis (LONDON:DPH) : April 20, 2017
finance.yahoo.com - April 20 at 4:53 PM |
| Dechra Pharmaceuticals Plc breached its 50 day moving average in a Bearish Manner : DPH-GB : April 19, 2017
finance.yahoo.com - April 19 at 12:28 PM |
| Dechra Pharmaceuticals plc (DPH) Price Target Raised to GBX 1,550
www.americanbankingnews.com - April 8 at 6:09 PM |
| Dechra Pharmaceuticals Plc : DPH-GB: Dividend Analysis : March 10th, 2017 (record date) : By the numbers : April 4, 2017
finance.yahoo.com - April 7 at 9:28 AM |
| Insider Selling: Dechra Pharmaceuticals plc (DPH) Insider Sells 3,500 Shares of Stock
www.americanbankingnews.com - March 23 at 4:28 AM |
| Dechra Pharmaceuticals plc (DPH) Given Add Rating at Numis Securities Ltd
www.americanbankingnews.com - March 20 at 12:27 AM |
 | Dechra® Pharmaceuticals PLC (LSE symbol DPH) Releases its 2017 Half-yearly Financial Report - PR Newswire (press release)
www.prnewswire.com - February 28 at 8:12 AM |
| Dechra® Pharmaceuticals PLC (LSE symbol DPH) Releases its 2017 Half-yearly Financial Report
finance.yahoo.com - February 27 at 7:36 PM |
| Half Year 2017 Dechra Pharmaceuticals PLC Earnings Release - Before Market Open
biz.yahoo.com - February 27 at 7:36 PM |
 | Why I’m avoiding these exciting growth shares right now
uk.finance.yahoo.com - February 16 at 2:55 PM |
| Should you make room for Pets At Home Group plc after today's update? - Yahoo Finance UK
uk.finance.yahoo.com - January 19 at 11:07 PM |
| Should you make room for Pets At Home Group plc after today’s update?
uk.finance.yahoo.com - January 19 at 6:06 PM |
| Does this pharma's 56% sales growth make it a better buy than GlaxoSmithKline plc? - Yahoo Finance UK
uk.finance.yahoo.com - January 17 at 8:22 AM |
| Dechra® Pharmaceuticals PLC Trading Update
finance.yahoo.com - January 17 at 8:22 AM |
| Does this pharma’s 56% sales growth make it a better buy than GlaxoSmithKline plc?
uk.finance.yahoo.com - January 17 at 8:22 AM |
| Could these top-performing stocks be about to collapse?
uk.finance.yahoo.com - November 7 at 5:46 AM |
 | Are These Pharma Fizzers 'Hot Buys' After Today's News?
www.forbes.com - October 21 at 4:44 PM |
Dechra Pharmaceuticals plc (DPH) Chart for Wednesday, September, 20, 2017
